<DOC>
	<DOCNO>NCT01101568</DOCNO>
	<brief_summary>This study Phase I , open-label , single-sequence drug interaction study evaluate effect repeat dos GSK1292263 pharmacokinetics rosuvastatin simvastatin healthy adult subject . Each subject receive single dos simvastatin rosuvastatin two occasion , alone follow administration repeat ( BID ) dose GSK1292263 .</brief_summary>
	<brief_title>A Study Investigate Interaction GSK1292263 With Rosuvastatin Simvastatin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female 18 65 year age inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential , define premenopausal female document tubal ligation bilateral oophorectomy hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea . If clinical situation unclear , FSH estradiol level may use confirm postmenopausal status Screening . Simultaneous follicle stimulate hormone ( FSH ) &gt; 40 mIU/ml estradiol &lt; 40pg/ml ( &lt; 140pmol/L ) confirmatory absence clear postmenopausal history . Male subject must agree use one contraception method list protocol . This criterion must follow time first dose study medication 5 terminal halflives ( i.e . 4 day ) postlast dose . Body weight great equal 50 kg BMI within range 19 30 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug/alcohol screen . A positive test HIV antibody . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Subjects cholelithiasis obstructive inflammatory gallbladder disease within 3 month prior Screening exclude . Gastrointestinal disease could affect fat bile acid absorption , pharmacokinetics pharmacodynamics study drug , include inflammatory bowel disease , chronic diarrhea , Crohn 's malabsorption syndrome within past year Gastrointestinal surgery may affect pharmacokinetics pharmacodynamics study drug Subjects may enrol study cholecystectomy three month time screen stable asymptomatic . Significant ECG abnormality , define protocol . Subjects Left Bundle Branch Block exclude study . Subjects partial Right Bundle Branch Block may consider inclusion follow consultation GSK Medical Monitor . Subjects WPW syndrome exclude study . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Subjects asthma history asthma , ( e.g. , FTIH risk bronchoconstriction unknown , compound specific risk bronchoconstriction ) . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Consumption red wine , seville orange , grapefruit grapefruit juice 7 day prior first dose study medication . CPK upper limit normal screening . Lactose intolerance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GSK1292263 , rosuvastatin , simvastatin , pharmacokinetics , drug interaction</keyword>
</DOC>